ReviewInteractive journal of medical research2025
Safety and Efficacy of Aspirin and Indobufen in the Treatment of Atherosclerotic Diseases: Systematic Review and Meta-Analysis.
Review in Interactive journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Migraine and risk of all-cause mortality and specific cause mortality: a systematic review and meta-analysis.The journal of headache and pain · 2025Pooled it
- Risk factors for drug-related gastrointestinal ulcer:a retrospective pharmacovigilance study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pathogenesis of atherosclerotic thrombosis primarily involves platelet activation and aggregation, making antiplatelet therapy the cornerstone of treatment for such diseases. Objective: This meta-analysis aimed to compare the safety and efficacy of aspirin and indobufen in antiplatelet therapy for patients with atherosclerotic diseases. Methods: We searched the Cochrane Library, PubMed, Embase, Web of Science, and the Chinese Wanfang databases. The literature was screened according to predefined inclusion and exclusion criteria. Risk ratio (RR) was used to assess the magnitude of risk associated with exposure and our inclusion criteria are as follows: (1) the study population comprised adults (aged 18 years and older) with coronary heart disease caused by coronary artery atherosclerosis or stroke caused by intracranial atherosclerosis; (2) the intervention was represented by indobufen in the study groups versus aspirin in the control groups; (3) the primary outcome was the incidence of major adverse cardiovascular and cerebrovascular events or any bleeding or Bleeding Academic Research Consortium 2/3/5 bleeding; (4) the secondary outcomes were cardiovascular death, myocardial infarction, and ischemic stroke; adverse cardiovascular events such as coronary thrombus reformation, heart failure, myocardial infarction, stroke, angina pectoris, and cardiovascular death; stroke; myocardial infarction; and cardiovascular death; and (5) the studies were randomized clinical trials with either crossover or parallel designs or prospective observational trials. Results: Eighteen trials with a total of 12,981 patients were included in this study. Compared to aspirin, indobufen reduced the risk of (1) bleeding events (RR 0.54, 95% CI 0.41-0.71; P<.0001), (2) Bleeding Academic Research Consortium 2/3/5 bleeding (RR 0.50, 95% CI 0.26-0.94; P=.03), (3) adverse cardiovascular events (RR 0.43, 95% CI 0.30-0.61; P<.00001), and (4) myocardial infarction (RR 0.60, 95% CI 0.41-0.89; P=.01). However, there were no significant differences between the 2 groups in terms of major adverse cardiovascular and cerebrovascular events, stroke, or cardiovascular mortality. Conclusions: Compared with aspirin, indobufen demonstrated better safety and was not inferior to aspirin in terms of efficacy, with superior results in some aspects (eg, fewer risks of adverse cardiovascular events and myocardial infarction). Further studies with larger sample sizes or longer follow-up periods may provide additional evidence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.